Previous 10 | Next 10 |
2023-10-04 10:26:12 ET More on Novartis Novartis: Buy This Dividend Aristocrat For Consistent Income Novartis: Q2 Beats Expectations, But Still Pricey Novartis: Strong Growth And Continued Expansion For KISQALI Novartis said to be considering a partial sale o...
2023-10-03 10:23:02 ET More on Novartis Novartis: Buy This Dividend Aristocrat For Consistent Income Novartis: Q2 Beats Expectations, But Still Pricey Novartis: Strong Growth And Continued Expansion For KISQALI Novartis readies Sandoz spinoff for trading on O...
2023-10-02 14:55:14 ET More on Bristol-Myers, Merck, etc. Bristol-Myers: Out Of Favor (Rating Upgrade) Bristol-Myers Squibb: How Cheap Is Cheap Enough? Bristol-Myers Squibb Looks Grossly Overvalued With LOE Taking A Bite Out Of Topline Merck, Bristol Myers, A...
2023-09-29 19:06:22 ET Carmot Therapeutics, which is developing drugs for diabetes and weight-loss, is reportedly mulling an IPO or possible sale to a large pharmaceutical company at a valuation of at least $1B. The biotech company has two injectable GLP-1 drug candidates in Phase 2 dev...
2023-09-29 15:00:29 ET More on the markets Historical Evidence Between Real Yields Suggests Further Slump For SPY Interest Rates Won't Be Higher For Longer: SPY Implications Rate environment today 'rhymes with 2008' - J.P. Morgan's Kolanovic Stocks in midst o...
2023-09-28 16:30:23 ET More on Teva, Novartis Novartis: Buy This Dividend Aristocrat For Consistent Income Teva: Focus On Innovation And Growth Means The Times They Are A Changing Eli Lilly benefits as judge overturns $176.5M verdict in Teva patent case Novar...
2023-09-28 16:18:43 ET More on Mirati Therapeutics Mirati: Expansion Of Adagrasib With sNDA And Combination Studies Mirati Therapeutics, Inc. 2023 Q2 - Results - Earnings Call Presentation Mirati Therapeutics, Inc. (MRTX) Q2 2023 Earnings Call Transcript Mira...
2023-09-26 07:17:48 ET Summary Novartis' core EPS payout ratio is poised to come in at around 51% in 2023. The Swiss drugmaker grew at a solid clip in the first half of this year. The company enjoys an AA- credit rating from ratings agency S&P. My inputs into the disco...
2023-09-25 12:25:28 ET More on Novartis Seeking Alpha’s Quant Rating on Novartis Historical earnings data for Novartis Dividend scorecard for Novartis Novartis: Q2 Beats Expectations, But Still Pricey Novartis: Strong Growth And Continued Expan...
2023-09-24 22:33:00 ET Summary Shanghai Everest Medicines acquired China/Asian rights to a novel therapy for autoimmune diseases from Kezar Life Sciences of South San Francisco in a deal worth $132.5 million. Once again, a big pharma has returned partnership rights for BeiGene...
News, Short Squeeze, Breakout and More Instantly...
2024-07-19 04:04:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-07-18 16:45:16 ET Image source: The Motley Fool. Novartis Ag (NYSE: NVS) Q2 2024 Earnings Call Jul 18, 2024 , 8:00 a.m. ET Operator Continue reading For further details see: Novartis Ag (NVS) Q2 2024 Earnings Call Transcript
2024-07-18 14:15:34 ET By most standards shares of drugmaker Novartis (NYSE: NVS) should be higher following this morning's release of its second-quarter results. The drugmaker's top and bottom lines were both better than expected, and up from year-earlier comparisons. And profit gu...